Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colin P Dinney

Showing results (91-100 of 202) with videos related to

Pageof 21
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancerArlene O Siefker-Radtke, Ashish M Kamat, H Barton Grossman, et al.
Translational Oncology|January 14, 2025
Molecular profiling of bladder cancer xenografts defines relevant molecular subtypes and provides a resource for biomarker discoverySharada Mokkapati, Ganiraju Manyam, Alexis R Steinmetz, et al.
European Urology|June 30, 2015
Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-GuérinAshish M Kamat, Joseph Briggman, Diana L Urbauer, et al.
International Journal of Cancer|March 29, 2002
Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimeticsFrank K Reiher, Olga V Volpert, Benilde Jimenez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2003
Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapyLance C Pagliaro, Afsaneh Keyhani, Dallas Williams, et al.
BJU International|June 3, 2015
Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapiesAshish M Kamat, Daniel L Willis, Rian J Dickstein, et al.
Molecular Cancer Therapeutics|May 10, 2013
Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancerKilian M Gust, David J McConkey, Shannon Awrey, et al.
Annals of Surgical Oncology|April 9, 2015
Genetic Variations in Glutathione Pathway Genes Predict Cancer Recurrence in Patients Treated with Transurethral Resection and Bacillus Calmette-Guerin Instillation for Non-muscle Invasive Bladder CancerHung-Lung Ke, Jie Lin, Yuanqing Ye, et al.
Carcinogenesis|January 17, 2013
Genetic variations in micro-RNA biogenesis genes and clinical outcomes in non-muscle-invasive bladder cancerHung-Lung Ke, Meng Chen, Yuanqing Ye, et al.
European Urology Oncology|June 16, 2019
Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not BenignRoger Li, Michael J Metcalfe, William B Tabayoyong, et al.
Pageof 21

Showing results (91-100 of 202) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancerArlene O Siefker-Radtke, Ashish M Kamat, H Barton Grossman, et al.
Translational Oncology|January 14, 2025
Molecular profiling of bladder cancer xenografts defines relevant molecular subtypes and provides a resource for biomarker discoverySharada Mokkapati, Ganiraju Manyam, Alexis R Steinmetz, et al.
European Urology|June 30, 2015
Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-GuérinAshish M Kamat, Joseph Briggman, Diana L Urbauer, et al.
International Journal of Cancer|March 29, 2002
Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimeticsFrank K Reiher, Olga V Volpert, Benilde Jimenez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2003
Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapyLance C Pagliaro, Afsaneh Keyhani, Dallas Williams, et al.
BJU International|June 3, 2015
Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapiesAshish M Kamat, Daniel L Willis, Rian J Dickstein, et al.
Molecular Cancer Therapeutics|May 10, 2013
Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancerKilian M Gust, David J McConkey, Shannon Awrey, et al.
Annals of Surgical Oncology|April 9, 2015
Genetic Variations in Glutathione Pathway Genes Predict Cancer Recurrence in Patients Treated with Transurethral Resection and Bacillus Calmette-Guerin Instillation for Non-muscle Invasive Bladder CancerHung-Lung Ke, Jie Lin, Yuanqing Ye, et al.
Carcinogenesis|January 17, 2013
Genetic variations in micro-RNA biogenesis genes and clinical outcomes in non-muscle-invasive bladder cancerHung-Lung Ke, Meng Chen, Yuanqing Ye, et al.
European Urology Oncology|June 16, 2019
Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not BenignRoger Li, Michael J Metcalfe, William B Tabayoyong, et al.
Pageof 21